Proactive Investors
10 Aug 2026, 06:26 UTC · 1h ago
ImmuPharma appoints Kymos as third Kapiglucagon partner in build towards clinic
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Proactive Investors
10 Aug 2026, 06:26 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
ImmuPharma has completed its outsourced development chain for its diabetes candidate Kapiglucagon by appointing Kymos Group as its bioanalytical partner. — Completing the infrastructure for IND filing is a critical milestone that moves the drug closer to human clinical trials.
+0.40Seeing Machines has secured a driver monitoring contract with a European carmaker valued at approximately $5 million in lifetime revenue. — Direct revenue growth and validation of technology, though the absolute dollar amount is relatively small.
+0.30ImmuPharma management is targeting a licensing deal for its principal value driver, the P140 autoimmune platform, within the current year. — A licensing deal would provide non-dilutive capital and external validation of the company's core technology.
+0.30Continue reading
6 related stories
Top 1 mover · tap to explore
ImmuPharma is evaluating an abbreviated 505(b)(2) FDA filing route for Kapiglucagon to potentially accelerate the approval process. — An abbreviated pathway reduces development time and costs compared to a full new drug application.
+0.20Which stocks this story touches
The company secured a $5 million driver monitoring contract amid new EU safety rules making the technology mandatory.
The company has completed its outsourced development chain for its diabetes candidate and is progressing toward a US IND application.
Mentioned as a selected partner for chemistry, manufacturing, and controls work.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
MarketBeat
13h ago
